| answer text |
<p>The National Institute for Health and Care Excellence (NICE) has not yet started
its evaluation of tofersen for treating amyotrophic lateral sclerosis caused by SOD1
gene mutations, and has therefore not published any guidance or recommendations on
whether tofersen should be available for National Health Service patients. In developing
its recommendations, the NICE will follow its published methods for health technology
evaluation, which will include a thorough assessment of the available evidence. This
takes into account all health-related costs and benefits, including health benefits
not only to patients but, where relevant, to other people such as carers. The NICE’s
aim is to publish its guidance on tofersen as close as possible to the date it receives
its marketing authorisation.</p>
|
 |
